Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct 20;115(10):1264–1272. doi: 10.1038/bjc.2016.325

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Cancer Research UK

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/

PMC Copyright notice

Three-year conditional overall and PFS experience of the total cohort (n=539) according to pretreatment uric acid levels. The empirical cut-off at the 75th percentile (Q3) was used for this analysis. Patients with elevated pretreatment uric acid levels (⩾Q3) initially had a worse 3-year conditional progression- and OS experience, which improved over time, and approached the 3-year COS and 3-year CPFS experience of patients with uric acid levels <Q3 after around 5 years of follow-up. Abbreviations: COS=conditional OS, CPFS=conditional PFS; UA=uric acid, Q3–75th percentile.